Research Focus:
Apellis is committed to improving the lives of patients with geographic atrophy and supports medical and scientific research that demonstrates the highest standards of scientific integrity, inclusivity, and intellectual curiosity. Submitted projects should focus on at least one of the following areas:
- Development of studies and tests to evaluate visual function in patients with GA due to AMD.
- Further understanding of the relationship between GA and neovascular AMD.
- Real world effectiveness of pegcetacoplan in patients with GA due to AMD.
- Effectiveness and safety of pegcetacoplan in patients with GA secondary to AMD with clinical features (phenotypes) not assessed in clinical trials (including but not limited to: bilateral GA patients treated in both eyes; GA patients with lesions approximately 200 microns or further from the foveal center).
- Effectiveness and safety of pegcetacoplan in GA due to AMD with different dosing intervals and dose escalation or de-escalation.
Review Process:
Applications to the Apellis US Retina Fellow Research Grant will be reviewed on a rolling basis up until the submission deadline on August 28, 2026. At the submission deadline, applications will be de-identified and reviewed based on the research merit criteria and alignment with the Apellis scientific areas of interest.
Timeline:
Following closure of the submission portal on August 28, applications will be reviewed as outlined above. The process is anticipated to take 3-4 weeks, at which point the applicant(s) with the selected submission will be notified. Following confirmation with the selected applicant, an announcement will be made regarding the selected project.